Table 4.
Social functioning and QOL score (determined by the PSP and EQ-5D)
| Item | Treatment group | Baseline | Week 26 | Week 52 | Week 104 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Score | Change from baseline | Score | Change from baseline | Score | Change from baseline at Week 104 | Change from 52-week score | ||||
| PSP | All groups | N | 251 | 105 | 105 | 77 | 77 | 52 | 52 | 50 |
| Total score | Mean (SD) | 56.3 (20.8) | 61.5 (21.5) | 5.4 (16.8)* | 61.4 (21.8) | 7.8 (17.7)* | 59.8 (24.1) | 4.1 (18.3) | −3.6 (16.5) | |
| Median | 60.0 | 65.0 | 0.0 | 65.0 | 0.0 | 65.0 | 0.0 | 0.0 | ||
| Min, max | 6, 100 | 4, 95 | −71, 73 | 6, 95 | −25, 74 | 6, 98 | −56, 55 | −74, 18 | ||
|
Aripiprazole group |
n | 82 | 34 | 34 | 23 | 23 | 14 | 14 | 12 | |
| Mean (SD) | 59.0 (21.0) | 67.5 (21.7) | 6.4 (15.7)* | 61.9 (25.8) | 5.9 (14.4) | 64.0 (27.8) | 8.3 (16.9) | 1.8 (9.6) | ||
| Median | 65.0 | 68.0 | 0.0 | 70.0 | 0.0 | 67.5 | 3.0 | 0.0 | ||
| Min, max | 6, 100 | 11, 95 | −21, 56 | 6, 95 | −19, 42 | 6, 96 | −15, 48 | −15, 18 | ||
|
Blonanserin group |
n | 85 | 37 | 37 | 27 | 27 | 15 | 15 | 15 | |
| Mean (SD) | 53.6 (21.1) | 60.0 (18.8) | 7.8 (16.9)* | 59.9 (23.2) | 9.5 (18.7)* | 55.5 (25.7) | 1.5 (27.6) | −8.8 (20.8) | ||
| Median | 60.0 | 65.0 | 1.0 | 65.0 | 1.0 | 61.0 | 0.0 | 0.0 | ||
| Min, max | 7, 85 | 10, 90 | −25, 73 | 6, 95 | −25, 66 | 9, 98 | −56, 55 | −61, 10 | ||
|
Paliperidone group |
n | 84 | 34 | 34 | 27 | 27 | 23 | 23 | 23 | |
| Mean (SD) | 56.5 (20.4) | 57.3 (23.3) | 1.9 (17.5) | 62.4 (16.7) | 7.7 (19.5) | 60.1 (21.0) | 3.1 (10.4) | −3.1 (15.8) | ||
| Median | 60.0 | 60.0 | 0.0 | 65.0 | 0.0 | 65.0 | 0.0 | 0.0 | ||
| Min, max | 6, 95 | 4, 95 | −71, 52 | 20, 95 | −7, 74 | 6, 95 | −8, 40 | −74, 11 | ||
| EQ-5D | All groups | n | 250 | 106 | 106 | 79 | 79 | 51 | 51 | 51 |
| (utility value) | Mean (SD) | 0.788 (0.167) | 0.834 (0.171) | 0.042 (0.166)* | 0.842 (0.164) | 0.048 (0.147)* | 0.893 (0.156) | 0.059 (0.179)* | 0.002 (0.130) | |
| Median | 0.771 | 0.786 | 0.000 | 0.804 | 0.000 | 1.000 | 0.000 | 0.000 | ||
| Min, max | 0.18, 1.00 | 0.12, 1.00 | −0.35, 0.52 | 0.41, 1.00 | −0.31, 0.53 | 0.47, 1.00 | −0.31, 0.52 | −0.31, 0.30 | ||
|
Aripiprazole group |
n | 82 | 34 | 34 | 25 | 25 | 14 | 14 | 14 | |
| Mean (SD) | 0.779 (0.168) | 0.829 (0.174) | 0.043 (0.198) | 0.831 (0.161) | 0.066 (0.179) | 0.867 (0.165) | 0.074 (0.210) | −0.011 (0.160) | ||
| Median | 0.771 | 0.786 | 0.000 | 0.768 | 0.000 | 1.000 | 0.032 | 0.000 | ||
| Min, max | 0.39, 1.00 | 0.47, 1.00 | −0.34, 0.47 | 0.59, 1.00 | −0.31, 0.53 | 0.59, 1.00 | −0.31, 0.39 | −0.31, 0.26 | ||
|
Blonanserin group |
n | 85 | 36 | 36 | 27 | 27 | 15 | 15 | 15 | |
| Mean (SD) | 0.768 (0.176) | 0.812 (0.189) | 0.048 (0.133)* | 0.814 (0.170) | 0.046 (0.133) | 0.830 (0.182) | 0.046 (0.181) | −0.017 (0.135) | ||
| Median | 0.768 | 0.786 | 0.000 | 0.786 | 0.000 | 0.804 | 0.000 | 0.000 | ||
| Min, max | 0.18, 1.00 | 0.12, 1.00 | −0.23, 0.34 | 0.41, 1.00 | −0.25, 0.34 | 0.47, 1.00 | −0.23, 0.34 | −0.30, 0.26 | ||
|
Paliperidone group |
n | 83 | 36 | 36 | 27 | 27 | 22 | 22 | 22 | |
| Mean (SD) | 0.818 (0.153) | 0.862 (0.148) | 0.034 (0.166) | 0.879 (0.160) | 0.033 (0.130) | 0.952 (0.111) | 0.059 (0.164) | 0.023 (0.107) | ||
| Median | 0.786 | 0.902 | 0.000 | 1.000 | 0.000 | 1.000 | 0.000 | 0.000 | ||
| Min, max | 0.48, 1.00 | 0.59, 1.00 | −0.35, 0.52 | 0.48, 1.00 | −0.30, 0.29 | 0.59, 1.00 | −0.21, 0.52 | −0.21, 0.30 | ||
There was no significant difference over 104 weeks between the groups (assessed using analysis of variance)
EQ-5D EuroQol-5 Dimension, max maximum, min minimum, PSP Personal and Social Performance Scale, QOL quality of life, SD standard deviation
*p < 0.05, for change from baseline assessment (paired t-test)